 |
7 Diseases |  |
1 Trial |
|
1 Trial |  |
200 News |  |
| «1234» |
- | Luzu (luliconazole) / Bausch Health
Preclinical, Journal: Formulation and Development of a Water-in-Oil Emulsion-Based Luliconazole Cream: In Vitro Characterization and Analytical Method Validation by RP-HPLC. (Pubmed Central) - Oct 5, 2022
Additionally, all validated parameters were obtained within the acceptable limit as well. These findings conclude that both physically and chemically stable w/o cream formulation of LCZ can be formulated and assessed for their stability by applying the authenticated analytical procedure of RP-HPLC.
- | Jublia (efinaconazole) / Kaken, Bausch Health, Luzu (luliconazole) / Bausch Health
Preclinical, Journal: Evaluation of Topical Antifungals Using a New Predictive Animal Model for Efficacy against Severe Tinea Unguium: A Comparison of Efinaconazole and Luliconazole. (Pubmed Central) - Sep 14, 2022
In addition, efinaconazole was more effective than luliconazole in reducing the nail fungal burden. Considering the relevance of clinical reports of the effectiveness of efinaconazole on severe onychomycosis, the new severe tinea unguium model would predict drug efficacy against moderate to severe onychomycosis.
- | Luzu (luliconazole) / Bausch Health
Journal: European Hedgehogs (Erinaceus europaeus L.) as a Reservoir of Dermatophytes in Poland. (Pubmed Central) - Sep 10, 2022
Although terbinafine generally exhibited high efficacy, two Trichophyton mentagrophytes isolates showed resistance to this drug (MIC = 2 µg/ml) resulting from missense mutations in the SQLE gene corresponding to the amino acid substitution Leu393Phe. Summarising, our study has also revealed that such wildlife animals as hedgehogs can be a reservoir of pathogenic human dermatophytes, including harmful strains resistant to commonly used antifungal drugs.
- | Luzu (luliconazole) / Bausch Health
Journal: First Isolation of Neoscytalidium dimidiatum from Human Dermatomycosis in Japan. (Pubmed Central) - Sep 10, 2022
The patient's lesions were cured by topical LLCZ. The clinical course and drug susceptibility suggest that LLCZ is a suitable first-line drug for treatment.
- | Luzu (luliconazole) / Bausch Health
Preclinical, Journal: Effect of Topical Antifungal Luliconazole on Hyphal Morphology of Trichophyton mentagrophytes Grown on in vitro Onychomycosis Model. (Pubmed Central) - Sep 7, 2022
On the other hand, when the nails were pretreated with luliconazole for 1 h, no hyphal growth was observed even after culturing for 24 h. This study suggests that luliconazole has a strong antifungal activity by inhibiting the ability of fungi to grow and the drug has both excellent nail permeation and retention properties.
- | Jublia (efinaconazole) / Kaken, Bausch Health, Luzu (luliconazole) / Bausch Health
Journal: A novel method for predicting the efficacy of topical drugs on onychomycosis: A comparison of efinaconazole and luliconazole. (Pubmed Central) - Aug 24, 2022
The established method enables the evaluation of nail permeability and anti-arthrospore activity of free-drugs in the nail plate to predict drug efficacy. This method will be useful for new topical drug development.
- | Luzu (luliconazole) / Bausch Health
Journal: Luliconazole topical dermal drug delivery for superficial fungal infections: Penetration hurdles and role of functional nanomaterials. (Pubmed Central) - Aug 22, 2022
In addition, nanotechnology and artificial neural network (ANN) derived integrated drug delivery systems may also be explored for augmenting the luliconazole therapeutic efficacy in topical fungal infections. Synergy of ANN models along with topical nanoscaled drug delivery may help to achieve critical quality attributes (CQA) to gain commercial success.
- || Jublia (efinaconazole) / Kaken, Bausch Health, Luzu (luliconazole) / Bausch Health, Kerydin (tavaborole) / Pfizer
Review, Journal: Dermatophytomas: Clinical Overview and Treatment. (Pubmed Central) - Jul 29, 2022
The density of fungal mass, and lack of adherence to the nail structures, as well as possible biofilm development, may play a role in the reduction in drug penetration and subsequent lack of efficacy with traditional oral therapies such as terbinafine and itraconazole...The topical antifungal solutions such as tavaborole, efinaconazole, and luliconazole may reach the dermatophytoma by both the transungual and subungual routes, due to low affinity for keratin and low surface tension...Similarly, fosravuconazole (F-RVCZ) has an improved pharmacological profile versus ravuconazole and may be an improved treatment option versus traditional oral therapies. The availability of improved treatments for dermatophytomas is crucial, as resistance to traditional therapies is on the increase.
- || Luzu (luliconazole) / Bausch Health
Review, Journal: The emergence of Trichophyton indotineae: Implications for clinical practice. (Pubmed Central) - Jul 23, 2022
Molecular studies have identified several point mutations in the ERG1 (terbinafine resistance) and ERG11 (azole resistance) genes, which need to be analyzed further. Use of relatively new agents, such as voriconazole and luliconazole, as well as device modalities and combination therapy, could be investigated for recalcitrant T. indotineae infections.
- || Luzu (luliconazole) / Bausch Health, Noxafil (posaconazole) / Merck (MSD)
Clinical, Journal: Multicenter Study of Susceptibility of Aspergillus Species Isolated from Iranian University Hospitals to Seven Antifungal Agents. (Pubmed Central) - Jul 2, 2022
The significant points of the present study are that species of Aspergillus section Flavi are the most prevalent Aspergillus species isolated from 11 university hospitals. Luliconazole, caspofungin, and isavuconazole were effective antifungal agents against all Aspergillus species.
- | Luzu (luliconazole) / Bausch Health
Preclinical, Journal: Luliconazole Nail Lacquer for the Treatment of Onychomycosis: Formulation, Characterization and In Vitro and Ex Vivo Evaluation. (Pubmed Central) - Jul 2, 2022
showed that LCZ-NL has comparatively higher growth inhibition than LULY™. Hence, developed LCZ-NL can be a promising topical drug delivery system for treating onychomycosis.
- | Astat (lanoconazole) / Maruho, Luzu (luliconazole) / Bausch Health
Preclinical, Journal: Eumycetoma Causative Agents are Inhibited in vitro by Luliconazole, Lanoconazole and Ravuconazole. (Pubmed Central) - Jun 4, 2022
The commonly encountered eumycetoma causative agents are inhibited by lanoconazole, luliconazole and ravuconazole. These drugs are promising candidates for further evaluation as potential treatment for eumycetoma.
- | Journal: Fusarium Keratitis in Taiwan: Molecular Identification, Antifungal Susceptibilities, and Clinical Features. (Pubmed Central) - May 30, 2022
The MICs of natamycin, voriconazole, chlorhexidine, lanoconazole, and luliconazole were higher for the FSSC than the non-FSSC, but no significant differences were noted in clinical outcomes, including corneal perforation and final visual acuity. In Taiwan, the FSSC was the most common complex in Fusarium keratitis; its MICs for five tested antifungal agents were higher than those of non-FSSC, but the clinical outcomes did not differ significantly.
- | Luzu (luliconazole) / Bausch Health
Journal: A deletion mutation in the amino acid sequence of squalene epoxidase in terbinafine-resistant Trichophytonrubrum. (Pubmed Central) - May 12, 2022
The protein of SQLE is the target of TRF, and it is essential for cell membrane synthesis in dermatophytes. However, dermatophyte cells were found to undergo gene mutations to escape the effects of antifungal agents.
- | Luzu (luliconazole) / Bausch Health
Preclinical, Journal: In Vitro and In Vivo Activity of Luliconazole (NND-502) against Planktonic Cells and Biofilms of Azole Resistant Aspergillus fumigatus. (Pubmed Central) - Apr 22, 2022
In vivo, single-dose LLCZ-treated larvae show a significantly higher survival percentage than the control group (20%). In conclusion, LLCZ has activity against planktonic cells and early biofilms of ARAF.
- | Luzu (luliconazole) / Bausch Health
Preclinical, Journal: Dermatokinetic assessment of luliconazole-loaded nanostructured lipid carriers (NLCs) for topical delivery: QbD-driven design, optimization, and in vitro and ex vivo evaluations. (Pubmed Central) - Apr 9, 2022
The T of both the formulations was found to be 6 h in the epidermis and dermis. The obtained results suggested that luliconazole NLCs can serve as a promising formulation to enhance luliconazole's antifungal activity and also in increasing patient compliance by reducing the frequency of application.
- || Luzu (luliconazole) / Bausch Health
PK/PD data, Journal: Preparation and partial pharmacodynamic studies of Luliconazole ethosomes. (Pubmed Central) - Apr 6, 2022
Besides, there was no skin irritation observed after treatment of luliconazole ethosomes. The luliconazole ethosomes are firstly prepared in our study, which have little stimulativeness, better permeation effect and antifungal activity, offering a new perspective for choosing clinical antifungal drug in department of dermatologry.
- || Luzu (luliconazole) / Bausch Health
Retrospective data, Review, Journal, Combination therapy: The effects of CO laser and topical agent combination therapy for onychomycosis: a meta-analysis. (Pubmed Central) - Apr 1, 2022
The higher satisfaction of the combined group was assessed by pooled effect (OR 4.56; 95% CI; 2.78-7.49; P <?0.00001). Our evidence suggests combined therapy may exert positive effects and satisfactory safety for patients with moderate to severe onychomycosis, however, optimal combination options and appropriate dosages require more comprehensive RCTs.
- | Luzu (luliconazole) / Bausch Health
Preclinical, Journal: A sensitive and rapid bioanalytical method for the quantitative determination of luliconazole in rabbit eye tissues using UPLC-MS/MS assay. (Pubmed Central) - Mar 16, 2022
Luliconazole was stable during the stability studies, including autosampler stability, benchtop stability, freeze/thaw stability and long-term stability. The method was successfully applied to the ocular pharmacokinetic and tissues distribution studies of LCZ in rabbit after topical administration of LCZ ophthalmic drug delivery system.
- || Jublia (efinaconazole) / Kaken, Bausch Health, Luzu (luliconazole) / Bausch Health
Clinical, Journal: Drug Sensitivity Profile of Fungi Isolated from Onychomycosis Patients and Evaluation of Squalene Epoxidase Mutation in One Terbinafine-Resistant Trichophyton mentagrophytes Species. (Pubmed Central) - Feb 23, 2022
The occurrence of resistant strains of organisms causing onychomycosis should be considered and evaluated. Furthermore, the identification of amino acid changes responsible for resistance to antifungals is a useful consideration in drug-target interaction.
- | terbinafine HCL / Generic mfg.
Preclinical, Journal: In Vitro Activities of 8 Antifungal Agents against Geophilic Dermatophyte Isolates. (Pubmed Central) - Feb 4, 2022
Luliconazole, terbinafine and efinaconazole exhibited the highest in vitro efficacy, regardless of the dermatophyte species. Further surveillance studies are recommended to confirm the implication of such in vitro data for the clinical recovery rate of dermatophytosis with geophilic species following antifungal therapy.
- || Luzu (luliconazole) / Bausch Health
Clinical, Journal: Etiological prevalence and antifungal sensitivity patterns of dermatophytosis in India - A multicentric study. (Pubmed Central) - Feb 3, 2022
Mean MIC of terbinafine was above the reference range, while it was within the range for itraconazole; griseofulvin had the lowest mean MIC. Luliconazole presented the lowest mean MIC values across cities.
- Luzu (luliconazole) / Bausch Health
The imidazole luliconazole is active against azole-resistant Aspergillus fumigatus (Hall L) - Jan 31, 2022 - Abstract #ECCMID2022ECCMID_1167;
- | Jublia (efinaconazole) / Kaken, Bausch Health, Luzu (luliconazole) / Bausch Health
Journal: Contact dermatitis caused by efinaconazole and luliconazole. (Pubmed Central) - Jan 18, 2022
However, the chemical formula of ravuconazole, an oral triazole antifungal drug, is similar to that of efinaconazole. Clinicians should carefully consider potential cross-reactivity between these drugs.
- | Luzu (luliconazole) / Bausch Health
Journal: Curcuma turmeric oil enhanced anti-dermatophytic drug activity against Candida albicans and Trichophyton mentagrophytes. (Pubmed Central) - Jan 18, 2022
Clinicians should carefully consider potential cross-reactivity between these drugs. It is concluded that the prepared luliconazole cream can be an effective anti-fungal treatment with enhanced drug delivery into the skin to treat athlete's foot and ringworm etc. caused by dermatophytes namely C. albicans and Trichophyton spp.
- || Luzu (luliconazole) / Bausch Health
Review, Journal: Multipotentiality of Luliconazole against Various Fungal Strains: Novel Topical Formulations and Patent Review. (Pubmed Central) - Jan 18, 2022
It is concluded that the prepared luliconazole cream can be an effective anti-fungal treatment with enhanced drug delivery into the skin to treat athlete's foot and ringworm etc. caused by dermatophytes namely C. albicans and Trichophyton spp. It has been concluded that luliconazole has exceptional potential in the treatment of various fungal infections, and therefore, it should be exploited to its maximum for its innovative application in the field of mycology.
- || terbinafine HCL / Generic mfg., voriconazole / Generic mfg.
Clinical, Journal: Molecular and MALDI-ToF MS Differentiation and Antifungal Susceptibility of Prevalent Clinical Fusarium Species in China. (Pubmed Central) - Jan 7, 2022
MALDI-ToF MS showed good performance in Fusarium species with an adapted Bruker library and expanded database. Fusarium isolates exhibited lower MICs to luliconazole and terbinafine compared to amphotericin B and voriconazole.
- | voriconazole / Generic mfg.
Journal: Genotypic diversity of Iranian Cryptococcus neoformans using multilocus sequence typing (MLST) and susceptibility to antifungals. (Pubmed Central) - Jan 1, 2022
Although seven sequence types belonging to C. neoformans isolates were detected, ST77 was the main sequence type in Ahvaz. Also, non-wild type isolates were only found against itraconazole and amphotericin B.
- | Luzu (luliconazole) / Bausch Health
Preclinical, Journal: Development and optimization of Luliconazole Nanostructured lipid carriers based gel by Quality by Design its skin distribution studies, dermatokinetic modeling & In-vitro and Ex-vivo correlation. (Pubmed Central) - Dec 21, 2021
Also, non-wild type isolates were only found against itraconazole and amphotericin B. The above findings revealed that developed LZ NC gel exhibited better permeation and localization at skin layers in treating fungal infections.
- | Luzu (luliconazole) / Bausch Health
Journal, Combination therapy: Carbon Dioxide Laser Plus Topical 5% Luliconazole: A Better Combination Therapeutic Modality for Onychomycosis. (Pubmed Central) - Dec 16, 2021
There were no severe adverse effects that warranted the discontinuation of the treatment in any of these patients. Fractional CO laser combined with topical luliconazole 5% lotion is a safe and effective treatment for onychomycosis especially in those who have contraindications to oral antifungals.
- || Luzu (luliconazole) / Bausch Health
Clinical, Journal: A Case of Tinea Pseudoimbricata Due to Trichophyton tonsurans Induced by Topical Steroid Application. (Pubmed Central) - Dec 16, 2021
After three months use of topical luliconazole cream, treatment was finished. We also summarize the knowledge about tinea pseudoimbricata through previous reports with bibliographical consideration.
- | Luzu (luliconazole) / Bausch Health
Preclinical, Journal: Genotyping and In Vitro Antifungal Susceptibility Profile of Neoscytalidium Species Isolates from Respiratory Tract. (Pubmed Central) - Nov 24, 2021
This is the first report of N. novaehollandiae isolation from respiratory tracts samples. Further study from other regions of the world with a larger set of clinical specimens is required to provide additional insight into diversity of Neoscytalidium species.
- || Luzu (luliconazole) / Bausch Health
Clinical, Journal: Therapeutic efficacy of topically used luliconazole vs. terbinafine 1% creams. (Pubmed Central) - Nov 17, 2021
Further study from other regions of the world with a larger set of clinical specimens is required to provide additional insight into diversity of Neoscytalidium species. Given the increasingly frequent reports of difficult-to-treat dermatophytoses caused by zoophilic terbinafine-resistant strains, the 1% luliconazole cream can be alternative solution in topical therapy.
- || Zalain (sertaconazole) / Elder Pharma, Luzu (luliconazole) / Bausch Health
Clinical, Journal, HEOR: Comparison of efficacy, safety, and cost-effectiveness of sertaconazole and luliconazole cream in patients with dermatophytoses: A prospective, randomized, open-label study. (Pubmed Central) - Nov 16, 2021
Only one patient in the sertaconazole group showed allergic contact dermatitis. Sertaconazole was better than luliconazole in relieving signs and symptoms during the study and follow-up period, but cost-effectiveness wise, luliconazole was better than sertaconazole.
- | terbinafine HCL / Generic mfg.
Preclinical, Journal: In vitro Antifungal susceptibility patterns of Trichophyton benhamiae complex isolates from diverse origin. (Pubmed Central) - Nov 6, 2021
Luliconazole, efinaconazole and terbinafine were the most potent antifungals against T benhamiae complex isolates, regardless of the geographic locations where strains were isolated. These data might help dermatologists to develop effective therapies for successful treatment of infections due to T benhamiae complex species.
- | Luzu (luliconazole) / Bausch Health
Journal: Solubility enhancement, formulation development and antifungal activity of luliconazole niosomal gel-based system. (Pubmed Central) - Oct 20, 2021
Based on the results, it can be concluded that niosomal luliconazole may enhance the activity of luliconazole against Candida albicans (C. albicans).
- | Luzu (luliconazole) / Bausch Health
Preclinical, Journal: Antifungal Agent Luliconazole Inhibits the Growth of Mouse Glioma-initiating Cells in Brain Explants. (Pubmed Central) - Oct 13, 2021
Furthermore, in brain slices, luliconazole inhibited the expansion of GIC-based tumors and the parenchymal infiltration of tumor cells. Our findings therefore indicate that luliconazole effectively targets GICs, thereby providing further support for the antitumorigenic effects of imidazole antifungal compounds.
- || terbinafine HCL / Generic mfg.
Clinical, Journal: Molecular identification and antifungal susceptibility profiles of Candida dubliniensis and Candida africana isolated from vulvovaginal candidiasis: A single-center experience in Iran. (Pubmed Central) - Oct 8, 2021
High MIC values were observed only for nystatin and terbinafine. Although C albicans remains the most common Candida species recovered from Iranian VVC/RVVC patients, our data show that its prevalence may be slightly overestimated due to the presence of difficult-to-identify closely related yeast, especially C africana.
- | voriconazole / Generic mfg.
Journal: Complementary effect of mechanism of multidrug-resistance in Trichophyton mentagrophytes isolated from human dermatophytoses of animal origin. (Pubmed Central) - Sep 23, 2021
In conclusion, our study shed more light on the role of the ABC transporter family in T. mentagrophytes, which, if overexpressed, can confer resistance to single azole drugs and even cross-resistance. Finally, milbemycin oxime could be an interesting compound supporting treatment with azole drugs in the case of refractory dermatomycoses.
- | Luzu (luliconazole) / Bausch Health
Journal: Antifungal susceptibility of dermatophytes from racehorses in Japan. (Pubmed Central) - Sep 19, 2021
LCZ demonstrated a broad spectrum of activity against clinical isolates from horse dermatophytoses. We consider that LCZ will become the primary antifungal agent for treating horse dermatophytosis.
- | Jublia (efinaconazole) / Kaken, Bausch Health, Luzu (luliconazole) / Bausch Health
Journal: Histopathology, Molecular Identification and Antifungal Susceptibility Testing of Nannizziopsis arthrosporioides from a Captive Cuban Rock Iguana (Cyclura nubila). (Pubmed Central) - Sep 5, 2021
The current study describes the first confirmed case of dermatomycosis caused by N. arthrosporioides of a captive reptile in Asia with detailed descriptions of the clinical, histopathological, and mycological features. The current findings provide new information on global distribution and host range of N. arthrosporioides and can raise the concern on the transboundary or emerging disease of N. arthrosporioides in Asian region.
- | Jublia (efinaconazole) / Kaken, Bausch Health, Luzu (luliconazole) / Bausch Health
Journal: A comparative study between two antifungal agents, Luliconazole and Efinaconazole, of their preventive effects in a Trichophyton-infected guinea pig onychomycosis model. (Pubmed Central) - Sep 5, 2021
The results suggest that LLCZ possesses longer-lasting antifungal effect in nails of the guinea pigs than EFCZ, and that this animal model could be useful for translational research between preclinical and clinical studies to evaluate the pharmacological efficacy of antifungal drugs to treat onychomycosis. This experimentally shown longer-lasting preventive effects of LLCZ could also decrease the likelihoods of onychomycosis recurrence clinically.
- || Luzu (luliconazole) / Bausch Health
Clinical, Journal: Molecular Identification and Antifungal Susceptibility among Clinical Isolates of Dermatophytes in Shiraz, Iran (2017-2019). (Pubmed Central) - Sep 4, 2021
In addition, infections due to zoophilic species showed an increasing trend. These epidemiological data, along with antifungal susceptibility patterns, may have implications for clinical decision-making and successful treatment.
- | Luzu (luliconazole) / Bausch Health
Preclinical, Journal: Luliconazole loaded lyotropic liquid crystalline nanoparticles for topical delivery: QbD driven optimization, in-vitro characterization and Dermatokinetic assessment. (Pubmed Central) - Aug 28, 2021
The total amount of drug penetrated (AUC) with LCNP formulation was 4.7 folds higher in epidermis and 6.5 folds higher in dermis than marketed cream. The study's findings vouch that LCNP can be a promising and effective carrier system for the delivery of antifungal drugs with enhanced skin permeation.
- | Luzu (luliconazole) / Bausch Health
Journal: Luliconazole vesicular based gel formulations for its enhanced topical delivery. (Pubmed Central) - Aug 25, 2021
In vivo antifungal activity on albino rats demonstrated vesicle based gel formulations to be safe, non irritant and more effective in topical treatment of fungal infections, with no drug reaching to systemic circulation. Thus, findings of the study demonstrate elastic liposomes and ethosomes, as a carrier are an attractive approach for enhanced topical delivery of Luliconazole.
- || Luzu (luliconazole) / Bausch Health
Clinical, Journal: Checkerboard analysis to evaluate synergistic combinations of existing antifungal drug and PGMC in isolates from recalcitrant tinea corporis and cruris harboring SQLE gene mutation. (Pubmed Central) - Aug 11, 2021
In vitro synergistic interactions provide a sound scientific basis for possible clinical use of antifungal combinations. Hence, these synergistic combinations may be tested for clinical utility in the wake of rising resistance among dermatophytic infections of the glabrous skin.
- | voriconazole / Generic mfg.
Preclinical, Journal: In vitro susceptibility of Aspergillus and Fusarium associated with equine keratitis to new antifungal drugs. (Pubmed Central) - Aug 8, 2021
Hence, these synergistic combinations may be tested for clinical utility in the wake of rising resistance among dermatophytic infections of the glabrous skin. The increased antifungal activity of luliconazole observed in this study warrants further investigation for its potential as an antifungal drug for equine fungal keratitis.
- | terbinafine HCL / Generic mfg.
Preclinical, Journal: A Mycological and Molecular Epidemiologic Study on Onychomycosis and Determination In Vitro Susceptibilities of Isolated Fungal Strains to Conventional and New Antifungals. (Pubmed Central) - Aug 3, 2021
The prevalence of onychomycosis in Iranian patients was relatively high. LUL exhibited potent antifungal activity against the three groups of fungi tested, determining its broad-spectrum antimycotic activity and its probable use as the first-line therapy for onychomycosis.
- | Olorofim (orotomide) / F2G
Preclinical, Journal: In vitro activity of the novel antifungal olorofim against dermatophytes and opportunistic moulds including Penicillium and Talaromyces species. (Pubmed Central) - Jul 10, 2021
LUL exhibited potent antifungal activity against the three groups of fungi tested, determining its broad-spectrum antimycotic activity and its probable use as the first-line therapy for onychomycosis. The potent in vitro activity of olorofim against drug-resistant dermatophytes and opportunistic moulds is promising, warranting evaluation of the clinical utility of olorofim.
- | voriconazole / Generic mfg.
Preclinical, Journal: In vitro antifungal susceptibility pattern of Candida species isolated from gastroesophageal candidiasis. (Pubmed Central) - Jul 6, 2021
Moreover, fluconazole- (6.5%) and itraconazole-resistant (2.1%) isolates were observed. With regard to the increase in fluconazole-resistant Candida species, it is necessary to determine the in vitro antifungal susceptibility pattern of clinical isolates for the best management of infection and to prevent the emergence of drug resistant isolates.